Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds

被引:26
作者
Dorfmueller, Helge C. [1 ]
van Aalten, Daan M. F. [1 ]
机构
[1] Univ Dundee, Coll Life Sci, Div Mol Microbiol, Dundee DD1 5EH, Scotland
基金
英国惠康基金;
关键词
O-GlcNAc; Posttranslational modification; Inhibitor; Crystal structure; BETA-N-ACETYLGLUCOSAMINIDASE; CELL DEATH; LINKED GLCNAC; NUCLEOCYTOPLASMIC PROTEINS; TETRATRICOPEPTIDE REPEATS; SIGNAL-TRANSDUCTION; CYTOSOLIC PROTEINS; LIGAND EFFICIENCY; IN-VIVO; STREPTOZOTOCIN;
D O I
10.1016/j.febslet.2009.12.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
O-GlcNAcylation is an essential posttranslational modification in metazoa. Modulation of O-GlcNAc levels with small molecule inhibitors of O-GlcNAc hydrolase (OGA) is a useful strategy to probe the role of this modification in a range of cellular processes. Here we report the discovery of novel, low molecular weight and drug-like O-GlcNAcase inhibitor scaffolds by high-throughput screening. Kinetic and X-ray crystallographic analyses of the binding modes with human/bacterial O-GlcNAcases identify some of these as competitive inhibitors. Comparative kinetic experiments with the mechanistically related human lysosomal hexosaminidases reveal that three of the inhibitor scaffolds show selectivity towards human OGA. These scaffolds provide attractive starting points for the development of non-carbohydrate, drug-like OGA inhibitors. (C) 2009 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:694 / 700
页数:7
相关论文
共 52 条
[1]
Ligand efficiency indices as guideposts for drug discovery [J].
Abad-Zapatero, C ;
Metz, JT .
DRUG DISCOVERY TODAY, 2005, 10 (07) :464-469
[2]
Molecular characterization of nucleocytosolic O-GlcNAc transferases of Giardia lamblia and Cryptosporidium parvum [J].
Banerjee, Sulagna ;
Robbins, Phillips W. ;
Samuelson, John .
GLYCOBIOLOGY, 2009, 19 (04) :331-336
[3]
BENNETT RA, 1981, CANCER RES, V41, P2786
[4]
Identification of Asp174 and Asp175 as the key catalytic residues of human O-GlcNAcase by functional analysis of site-directed mutants [J].
Çetinbas, N ;
Macauley, MS ;
Stubbs, KA ;
Drapala, R ;
Vocadlo, DJ .
BIOCHEMISTRY, 2006, 45 (11) :3835-3844
[5]
CHOU CF, 1992, J BIOL CHEM, V267, P3901
[6]
Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a β-N-acetylglucosaminidase [J].
Comtesse, N ;
Maldener, E ;
Meese, E .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 283 (03) :634-640
[7]
Structure and mechanism of a bacterial β-glucosaminidase having O-GlcNAcase activity [J].
Dennis, RJ ;
Taylor, EJ ;
Macauley, MS ;
Stubbs, KA ;
Turkenburg, JP ;
Hart, SJ ;
Black, GN ;
Vocadlo, DJ ;
Davies, GJ .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2006, 13 (04) :365-371
[8]
DONG DLY, 1994, J BIOL CHEM, V269, P19321
[9]
GlcNAcstatin:: A picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-GlcNAcylation levels [J].
Dorfmueller, Helge C. ;
Borodkin, Vladimir S. ;
Schimpl, Marianne ;
Shepherd, Sharon M. ;
Shpiro, Natalia A. ;
van Aalten, Daan M. F. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (51) :16484-16485
[10]
GIcNAcstatins are nanomolar inhibitors of human O-GIcNAcase inducing cellular hyper-O-GIcNAcylation [J].
Dorfmueller, Helge C. ;
Borodkin, Vladimir S. ;
Schimpl, Marianne ;
van Aalten, Daan M. F. .
BIOCHEMICAL JOURNAL, 2009, 420 :221-227